Investment Managers Series Trus (IREX)

Key Updates

IREX declined a further -3.84% since the 14 September report, falling to $14.79 and extending the year-to-date loss to -51.28%. The 5-day decline accelerated to -18.29%, indicating a sharp acceleration of the existing downtrend. The single new news item (BMO/REX MNGU launch) is sector-related but not company-specific, and does not alter the fundamental thesis.

Current Trend

The dominant trend remains strongly bearish. IREX has fallen from $17.60 (9 September) to $14.79 (15 September), a -15.97% decline over four trading sessions. The 6-month decline of -45.28% and YTD decline of -51.28% confirm a persistent, multi-month downtrend with no signs of stabilization. The 1-day move of -2.50% on 15 September suggests continued selling pressure without any reversal signal.

Investment Thesis

The investment thesis remains unchanged: IREX is in a sustained bear market driven by broad-based selling pressure. The fund's price action shows no company-specific positive catalysts in the provided news flow, which is dominated by leveraged ETF/ETN launches from competitors (BMO, REX, Leverage Shares, Tradr, Direxion) — none of which relate to IREX's underlying holdings or strategy. The thesis of continued decline remains intact.

Thesis Status

The bearish thesis is confirmed and strengthening. Each successive report has shown accelerating losses: -2.00% (9 Sep), -10.00% (10 Sep), -2.90% (14 Sep), and now -3.84% (15 Sep). The price has broken through prior levels without any support emerging. No fundamental or technical counter-signals appear in the provided data.

Key Drivers

The primary driver remains persistent market-wide selling pressure affecting IREX. The provided news flow is dominated by competitor product launches in the leveraged ETF space, including BMO/REX sector ETNs, Leverage Shares Anthropic filings, and Direxion Anthropic products. These do not directly affect IREX's holdings but indicate heightened competition for investor capital in the leveraged product space. The MNGU launch (26 August) is the only news item in the current report window and is likewise unrelated to IREX's specific strategy.

Technical Analysis

IREX is trading at $14.79, having broken below the $15.00 psychological level. The price action shows a clean breakdown from the $17.60–$15.84 range established in early September. Immediate support appears absent, with the next potential level being the $14.00 area based on the magnitude of recent daily declines. Resistance is now overhead at $15.38 (14 September close) and $15.84 (10 September close). The 5-day return of -18.29% versus the 1-month return of -13.31% indicates the selling pressure is intensifying, not abating.

Bull Case

• The 6-month decline of -45.28% may represent an oversold condition, potentially attracting value-oriented buyers seeking mean reversion, though no fundamental catalyst is present in the provided data.
• The MNGU launch demonstrates continued innovation in the AI-focused leveraged product space, which could indirectly support sentiment for AI-related funds, though IREX's specific exposure is not detailed.
• No company-specific negative news has been reported, suggesting the decline is market-driven rather than idiosyncratic, which could reverse if market sentiment improves.
• If the broader market stabilizes after the recent sharp declines, IREX could see a technical rebound from oversold levels, given the magnitude of the 5-day drop.
• The absence of any negative fundamental developments in the news flow leaves room for a potential recovery if external market conditions improve.

Bear Case

• The accelerating decline — YTD -51.28%, 6-month -45.28%, and 5-day -18.29% — shows no sign of deceleration, indicating persistent institutional selling with no identified support level.
• The price has broken through the $15.00 psychological level with no bounce, signaling weak buyer interest and potential for further downside.
• Competitive pressure from the proliferation of new leveraged products (BMO/REX, Leverage Shares, Tradr, Direxion) may be diverting capital away from existing funds like IREX.
• The ongoing wave of new ETF filings suggests the market is crowded with similar leveraged products, potentially reducing demand for IREX's specific strategy.
• The continued negative price action across all timeframes (1d, 5d, 1m, 6m, YTD) confirms a persistent downtrend with no reversal signals in the provided data.